{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:09:27Z","timestamp":1791461367141,"version":"4.3.4"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T00:00:00Z","timestamp":1386288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0081480","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T16:24:44Z","timestamp":1386347084000},"page":"e81480","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Telmisartan Ameliorates Fibrocystic Liver Disease in an Orthologous Rat Model of Human Autosomal Recessive Polycystic Kidney Disease"],"prefix":"10.1371","volume":"8","author":[{"given":"Daisuke","family":"Yoshihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Kugita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold M.","family":"Aukema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamio","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuko","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,12,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.med.60.101707.125712","article-title":"Polycystic kidney disease","volume":"60","author":"PC Harris","year":"2009","journal-title":"Annu Rev Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrneph.2011.109","article-title":"Why kidneys fail in autosomal dominant polycystic kidney disease","volume":"7","author":"JJ Grantham","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00467-010-1656-1","article-title":"Diagnosis and management of childhood polycystic kidney disease","volume":"26","author":"WE Sweeney Jr","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00247-008-1064-x","article-title":"Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis (ARPKD\/CHF)","volume":"39","author":"B Turkbey","year":"2009","journal-title":"Pediatr Radiol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpeds.2006.03.014","article-title":"Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health\/Office of Rare Diseases conference","volume":"149","author":"M Gunay-Aygun","year":"2006","journal-title":"J Pediatr"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Gunay-Aygun M, Font-Montgomery E, Lukose L, Tuchman Gerstein M, Piwnica-Worms K, <etal>et al<\/etal>.. (2013) Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. Gastroenterology 144: 112\u2013121 e112.","DOI":"10.1053\/j.gastro.2012.09.056"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1007\/s00467-010-1621-z","article-title":"The renin-angiotensin system and hypertension in autosomal recessive polycystic kidney disease","volume":"25","author":"M Goto","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1517\/14656566.5.11.2397","article-title":"Telmisartan - killing two birds with one stone","volume":"5","author":"SA Doggrell","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"658520","DOI":"10.1155\/2008\/658520","article-title":"PPAR Regulation of Inflammatory Signaling in CNS Diseases","volume":"2008","author":"JJ Bright","year":"2008","journal-title":"PPAR Res"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Liu C, Zhang Y, Yuan L, Fu L, Mei C (2013) Rosiglitazone inhibits insulin-like growth factor1-induced polycystic kidney disease cell growth and p70S6 kinase activation. Mol Med Rep. In press.","DOI":"10.2119\/molmed.2012.00339"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.molmed.2012.03.004","article-title":"PPARgamma as a therapeutic target in cystic fibrosis","volume":"18","author":"JF Dekkers","year":"2012","journal-title":"Trends Mol Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.tox.2012.06.015","article-title":"Telmisartan treatment attenuates arsenic-induced hepatotoxicity in mice","volume":"300","author":"AA Fouad","year":"2012","journal-title":"Toxicology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.bbrc.2007.10.083","article-title":"Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet","volume":"364","author":"H Jin","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"F465","DOI":"10.1152\/ajprenal.00460.2010","article-title":"PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease","volume":"300","author":"D Yoshihara","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"695898","DOI":"10.1155\/2012\/695898","article-title":"Global Gene Expression Profiling in PPAR-gamma Agonist-Treated Kidneys in an Orthologous Rat Model of Human Autosomal Recessive Polycystic Kidney Disease","volume":"2012","author":"D Yoshihara","year":"2012","journal-title":"PPAR Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2174\/1874467211205020292","article-title":"PPAR-gamma agonists in polycystic kidney disease with frequent development of cardiovascular disorders","volume":"5","author":"S Nagao","year":"2012","journal-title":"Curr Mol Pharmacol"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, <etal>et al<\/etal>.. (2013) Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med. In press.","DOI":"10.1111\/dme.12144"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Hsiao FY, Hsieh PH, Huang WF, Tsai YW, Gau CS (2013) Risk of Bladder Cancer in Diabetic Patients Treated with Rosiglitazone or Pioglitazone: A Nested Case-Control Study. Drug Saf. In press.","DOI":"10.1007\/s40264-013-0080-4"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e3645","DOI":"10.1136\/bmj.e3645","article-title":"The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study","volume":"344","author":"L Azoulay","year":"2012","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ng833","article-title":"The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein","volume":"30","author":"CJ Ward","year":"2002","journal-title":"Nat Genet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1681\/ASN.2006030251","article-title":"Increased water intake decreases progression of polycystic kidney disease in the PCK rat","volume":"17","author":"S Nagao","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2353\/ajpath.2007.070337","article-title":"Cholangiocytes with mesenchymal features contribute to progressive hepatic fibrosis of the polycystic kidney rat","volume":"171","author":"Y Sato","year":"2007","journal-title":"Am J Pathol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF00788278","article-title":"Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light","volume":"89","author":"P Whittaker","year":"1994","journal-title":"Basic Res Cardiol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3748\/wjg.v19.i9.1380","article-title":"Hepatic regeneration and the epithelial to mesenchymal transition","volume":"19","author":"ZF Xue","year":"2013","journal-title":"World J Gastroenterol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis","volume":"134","author":"SL Friedman","year":"2008","journal-title":"Gastroenterology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0002-9149(99)00727-4","article-title":"Angiotensin II receptor blockers: review of the binding characteristics","volume":"84","author":"H Siragy","year":"1999","journal-title":"Am J Cardiol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/hr.2010.67","article-title":"Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy","volume":"33","author":"V Sukumaran","year":"2010","journal-title":"Hypertens Res"},{"key":"ref28","first-page":"263","article-title":"Clinical eyaspects of autosomal recessive polycystic kidney disease","volume":"32","author":"NF Dias","year":"2010","journal-title":"J Bras Nefrol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4103\/1319-3767.77251","article-title":"Carvedilol in the treatment of portal hypertension","volume":"17","author":"H Al-Ghamdi","year":"2011","journal-title":"Saudi J Gastroenterol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1100\/tsw.2010.213","article-title":"The nuclear hormone receptor PPARgamma as a therapeutic target in major diseases","volume":"10","author":"MV Schmidt","year":"2010","journal-title":"ScientificWorldJournal"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"18779","DOI":"10.1074\/jbc.272.30.18779","article-title":"The organization, promoter analysis, and expression of the human PPARgamma gene","volume":"272","author":"L Fajas","year":"1997","journal-title":"J Biol Chem"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/labinvest.2008.104","article-title":"PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta","volume":"89","author":"T Kawai","year":"2009","journal-title":"Lab Invest"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbrc.2006.09.069","article-title":"PPARgamma agonists prevent TGFbeta1\/Smad3-signaling in human hepatic stellate cells","volume":"350","author":"C Zhao","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1042\/CS20100113","article-title":"Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats","volume":"119","author":"B Dai","year":"2010","journal-title":"Clin Sci (Lond)"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"e28915","DOI":"10.1371\/journal.pone.0028915","article-title":"Rosiglitazone inhibits transforming growth factor-beta1 mediated fibrogenesis in ADPKD cyst-lining epithelial cells","volume":"6","author":"Y Liu","year":"2011","journal-title":"PLoS One"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/s00592-005-0176-0","article-title":"Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator","volume":"42","author":"TW Kurtz","year":"2005","journal-title":"Acta Diabetol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3317\/jraas.2007.017","article-title":"Renoprotective effects of telmisartan in the 5\/6 nephrectomised rats","volume":"8","author":"I Tsunenari","year":"2007","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/s00592-007-0016-5","article-title":"Renoprotective effects of telmisartan on renal injury in obese Zucker rats","volume":"49","author":"T Ohmura","year":"2012","journal-title":"Acta Diabetol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1734-1140(11)70611-9","article-title":"Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats","volume":"63","author":"BR Goyal","year":"2011","journal-title":"Pharmacol Rep"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/aps.2011.96","article-title":"Regulation of angiotensin-(1\u20137) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure","volume":"32","author":"WN Zong","year":"2011","journal-title":"Acta Pharmacol Sin"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10735-012-9441-z","article-title":"Comparative study of three angiotensin II type 1 receptor antagonists in preventing liver fibrosis in diabetic rats: stereology, histopathology, and electron microscopy","volume":"43","author":"S Sipal","year":"2012","journal-title":"J Mol Histol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"R1063","DOI":"10.1152\/ajpregu.00281.2004","article-title":"Administration of ANG II induces iron deposition and upregulation of TGF-beta1 mRNA in the rat liver","volume":"288","author":"N Ishizaka","year":"2005","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/hep.20665","article-title":"Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats","volume":"41","author":"R Bataller","year":"2005","journal-title":"Hepatology"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0081480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T12:23:23Z","timestamp":1564921403000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0081480"}},"subtitle":[],"editor":[{"given":"Giovanni Li","family":"Volti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":43,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0081480","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}